Skip to main content
Premium Trial:

Request an Annual Quote

GNS Healthcare, Brigham & Women's Collaborate on Adverse Drug Events Prediction

NEW YORK (GenomeWeb News) – GNS Healthcare today said that it will collaborate with researchers at Brigham & Women's Hospital on predicting adverse drug events and hospital readmissions for patients who have been admitted for congestive heart failure.

The alliance will use GNS' Reverse Engineering-Forward Simulation (REFS) platform as well as data from electronic health records of patients treated by the Partners HealthCare system. The partners will attempt to identify hidden, underlying pathways and relationships that lead to adverse events.

GNS will work with David Bates, chief of the division of General Internal Medicine and Primary Care at Brigham & Women's Hospital and a professor of medicine at Harvard Medical School. Bates said that the collaboration has the "potential to dramatically increase the quality of patient care while reducing overall healthcare costs."

Cambridge, Mass.-based GNS, which is a subsidiary of VIA Science, said that preventable adverse drug events are estimated to cost the US healthcare system as much as $50 billion a year.

The firm's REFS platform is comprised of "integrated machine learning algorithms and software that extract causal relationships from complex, multi-dimensional data," enabling the simulation of billions of hypotheses that "explore novel unseen conditions and predictions," it said.

GNS recently inked collaborative agreements with Bristol-Myers Squibb to discover new biomarkers and uncover new disease biology related to immune-inflammation and with the National Cancer Institute to help determine what treatments may work best for individuals with non-small cell lung cancer.

The Scan

Study Follows Consequences of Early Confirmatory Trials for Accelerated Approval Indications

Time to traditional approval or withdrawal was shorter when confirmatory trials started prior to accelerated approval, though overall regulatory outcomes remained similar, a JAMA study finds.

Sequencing Study Leads to Vaccine Target in Bacteria Behind Neonatal Meningitis

Researchers eBioMedicine track down potential vaccine targets with transposon sequencing on mutant bacteria causing neonatal meningitis in mouse models of the disease.

Multiple Myeloma Progression Influenced by Immune Microenvironment Expression

Researchers in NPJ Genomic Medicine compare RNA sequencing profiles of 102,207 individual cells in bone marrow samples from 18 individuals with rapid or non-progressing multiple myeloma.

Self-Reported Hearing Loss in Older Adults Begins Very Early in Life, Study Says

A JAMA Otolaryngology — Head & Neck Surgery study says polygenic risk scores associated with hearing loss in older adults is also associated with hearing decline in younger groups.